Part VI: Summary of the risk management plan

Summary of risk management plan for

Rivaroxaban Grindeks

(rivaroxaban)

This is a summary of the risk management plan (RMP) for Rivaroxaban Grindeks. The RMP details important risks of Rivaroxaban Grindeks, how these risks can be minimised, and how more information will be obtained about Rivaroxaban-Grindeks risks and uncertainties (missing information).

Rivaroxaban Grindeks's summary of product characteristics (SPC) and its package leaflet give essential information to healthcare professionals and patients on how Rivaroxaban Grindeks should be used.

Important new concerns or changes to the current ones will be included in updates of Rivaroxaban Grindeks's RMP.

I. The medicine and what it is used for

Rivaroxaban -Grindeks is indicated for prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery and for treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. It contains rivaroxaban as the active substance and it is given by oral route of administration in concentration of 10 mg, 15mg or 20 mg per film coated tablet.

II. Risks associated with the medicine and activities to minimise or further characterise the risks

Important risks of Rivaroxaban Grindeks, together with measures to minimise such risks and the proposed studies for learning more about risks of Rivaroxaban Grindeks, are outlined below.

Measures to minimise the risks identified for medicinal products can be:

- Specific information, such as warnings, precautions, and advice on correct use, in the package leaflet and SPC addressed to patients and healthcare professionals;
- Important advice on the medicine's packaging;
- The authorised pack size – the amount of medicine in a pack is chosen so to ensure that the medicine is used correctly;
- The medicine's legal status – the way a medicine is supplied to the patient (e.g. with or without prescription) can help to minimise its risks.

Together, these measures constitute routine risk minimisation measures.

In addition to these measures, information about adverse reactions is collected continuously and regularly analysed so that immediate action can be taken as necessary. These measures constitute routine pharmacovigilance activities.

If important information that may affect the safe use of Rivaroxaban Grindeks is not yet available, it is listed under "missing information" below.

II.A List of important risks and missing information

Important risks of Rivaroxaban Grindeks are risks that need special risk management activities to further investigate or minimise the risk, so that the medicinal product can be safely administered. Important risks can be regarded as identified or potential. Identified risks are concerns for which there is sufficient proof of a link with the use of Rivaroxaban Grindeks. Potential risks are concerns for which an association with the use of this medicine is possible based on available data, but this association has not been established yet and needs further evaluation. Missing information refers to information on the safety of the medicinal product that is currently missing and needs to be collected (e.g. on the long-term use of the medicine).

Summary of safety concerns	
Important identified risks	*Haemorrhage*
Important potential risks	*Embryo-fetal toxicity*
Missing information	*Remedial pro-coagulant therapy for excessive haemorrhage* *Patients with atrial fibrillation (AF) and a prosthetic heart valve*

II.B Summary of important risks

Important identified risk - Haemorrhage	
Risk minimisation measures	Routine risk minimisation measures: SPC section 4.3., 4.4. and 4.8 Prescription-only medicine Limited pack size. Additional risk minimisation measures: Educational material for prescribers Patient alert cards

II.C Post-authorisation development plan

II.C.1 Studies which are conditions of the marketing authorisation

There are no studies which are conditions of the marketing authorisation or specific obligation of Rivaroxaban Grindeks.

II.C.2 Other studies in post-authorisation development plan

There are no studies required for Rivaroxaban Grindeks.